舒尼替尼
肾细胞癌
癌症研究
脂质代谢
新陈代谢
化学
内科学
医学
作者
Zhihao Wei,Yuzhong Ye,Chenchen Liu,Qi Wang,Yunxuan Zhang,Kailei Chen,Ge Cheng,Xiaoping Zhang
标识
DOI:10.1016/j.jare.2024.04.032
摘要
Renal cell carcinoma (RCC) is one of the most common malignant tumors of the urinary system and accounts for more than 90 % of all renal tumors. Resistance to targeted therapy has emerged as a pivotal factor that contributes to the progressive deterioration of patients with advanced RCC. Metabolic reprogramming is a hallmark of tumorigenesis and progression, with an increasing body of evidence indicating that abnormal lipid metabolism plays a crucial role in the advancement of renal clear cell carcinoma.
科研通智能强力驱动
Strongly Powered by AbleSci AI